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ABSTRACT
In total, 120 Escherichia coli isolates positive for one
of the gentamicin resistance (GENR) genes aac(3)-
II, aac(3)-IV or ant(2¢¢)-I were tested for gentamicin
susceptibility by the agar dilution method. Isolates
positive for aac(3)-IV or ant(2¢¢)-I had an MIC
distribution of 8–64 mg ⁄L, whereas isolates posit-
ive for aac(3)-II had MICs of 32 to >512 mg ⁄L,
suggesting a relationship between the distribution
of MICs and the specific GENR mechanism. The
MIC distribution, regardless of the GENR mech-
anism, was 8 - >512 mg ⁄L, which supports the
clinical breakpoint of MIC >4 mg ⁄L suggested by
EUCAST and questions the breakpoint recom-
mended by the CLSI (‡16 mg ⁄L).
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Gentamicin was introduced in 1963 as the first
clinically useful broad-spectrum antimicrobial
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 816–842
Corresponding author and reprint requests: L. Jakobsen,
National Center for Antimicrobials & Infection Control,
Statens Serum Institut, Artillerivej 5, Building 47, Room 201,
DK-2300 Copenhagen S, Denmark
E-mail: lja@ssi.dk
830 Clinical Microbiology and Infection, Volume 13 Number 8, August 2007
agent, and it remains one of the most powerful
antibiotics for treatment of serious infections [1].
Gentamicin resistance (GENR)—first reported in
1967—can be caused by aminoglycoside-modify-
ing enzymes that are grouped as either o-phos-
photransferases (APHs), N-acetyltransferases
(AACs) or o-adenyltransferases (ANTs) [2]. A
correlation between the enzyme produced and
the level of resistance to different aminoglyco-
sides has been demonstrated previously [3].
Enzymes encoded by aac(3)-II, aac(3)-IV and
ant(2¢¢)-I are now detected more frequently in
Escherichia coli isolates of human, food, animal
and environmental origin [4–9]. These genes,
which confer cross-resistance to other aminogly-
cosides, can be mobilised on multiresistance
elements, so that the spread of GENR determi-
nants is likely to be selected by antimicrobial
agents other than gentamicin [2,6,10].
To ensure efficient antibiotic therapy for
bacterial infections, validated data concerning
MIC breakpoints are vital. The European
Committee on Antimicrobial Susceptibility
Testing (EUCAST) is attempting to harmonise
species-related MIC breakpoints in Europe [11],
while standardisation of MIC breakpoints in the
USA is undertaken by the CLSI [12]. The objective
of the present study was to investigate whether a
relationship exists between the aac(3)-II, aac(3)-IV
and ant(2¢¢)-I GENR mechanisms, and the MIC
distribution for gentamicin.
The study included 120 E. coli isolates from
different sources that were positive for the GENR
genes aac(3)-II, aac(3)-IV or ant(2¢¢)-I: (i) 31 isolates
from patients with urinary tract infections; (ii) 55
isolates from wastewater; and (iii) 34 isolates of
animal origin. All isolates had been screened
previously by PCR for the presence of aac(3)-II,
aac(3)-IV and ant(2¢¢)-I [13] (personal unpublished
data). Susceptibility to gentamicin was determined
using an agar dilution method (4–512 mg ⁄L)
according to the CLSI standard procedure [12],
using gentamicin (Sandoz A ⁄ S, Odense, Denmark)
and Mueller–Hinton agar (Oxoid, Basingstoke,
UK). Six isolates with a gentamicin MIC of
8 mg ⁄L, as determined by the agar dilution
method, were further analysed by disk-diffusion,
using the methods described by the Swedish
Reference Group on Antibiotics (SRGA) (http://
www.srga.org/RAFMETOD/rafmet.htm) and the
CLSI, respectively [14]. E. coli ATCC 25922 was
used as a quality control strain in all tests.
Of the 120 isolates, 52 were positive for aac(3)-II,
58 for aac(3)-IV and ten for ant(2¢¢)-I. None of the
isolates carried more than one of the three genes
tested. Isolates positive for aac(3)-IV or ant(2¢¢)-I
had an MIC range of 8–64 mg ⁄L, whereas the
isolates positive for aac(3)-II had an MIC range of
32 - >512 mg ⁄L (Fig. 1), suggesting that a rela-
tionship exists between the MIC distribution and
specific GENR mechanisms. Regardless of GENR
background, the MIC distribution spanned the
range 8 - >512 mg ⁄L, and thus supported the
EUCAST clinical breakpoint of MIC >4 mg ⁄L. If
the breakpoint of ‡16 mg ⁄L recommended by the
CLSI [12] was used, isolates positive for aac(3)-IV
or ant(2¢¢)-I that exhibited low levels of resistance
(8 mg ⁄L) would not be detected. Thus, only 92%
(n = 53) of the aac(3)-IV-positive isolates and 90%
(n = 9) of the ant(2¢¢)-I-positive isolates would
have been detected. This difference in interpret-
ation between the European and the US recom-
mendations could result in an underestimate of
GENR E. coli isolates if the CLSI breakpoint
instead of the EUCAST breakpoint was used,
with possible serious consequences for patients.
Using the SRGA disk-diffusion method, only
two of the six isolates with MICs of 8 mg ⁄L that
were positive for aac(3)-IV or ant(2¢¢)-I were
interpreted as GENR. In contrast, the CLSI
disk-diffusion method interpreted four of these
six isolates as GENR (Table 1). Isolates inter-
preted as non-resistant by either method were
interpreted as intermediate. Further investiga-
tions are required to determine whether inter-
pretation standards for disk-diffusion need to
be reassessed, or whether these results reflect
variations in the methods.
The finding of isolates positive for aac(3)-IV or
ant(2¢¢)-I with MICs of 8 mg ⁄L raised the question
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Fig. 1. Distribution of gentamicin MICs for Escherichia coli
isolates carrying aac(3)-II (n = 52), aac(3)-IV (n = 58) or
ant(2¢¢)-I (n = 10).
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of whether similar isolates with an MIC of 4 mg ⁄L
exist. This seems likely, since strains with an MIC
of 8 mg ⁄L would sometimes be recorded as
having an MIC of 4 mg ⁄L simply because of
method variation. No isolates with MICs
<8 mg ⁄L were found in the present study;
similarly, the EUCAST ‘Antimicrobial wild-type
distributions of microorganisms’ database
(http://217.70.33.99/Eucast2/), which contains
results for >30 000 clinical E. coli isolates, also
contained no isolates with a gentamicin MIC of
4 mg ⁄L. A normal distribution of MIC values
would be expected in a database of this size, but
>9000 isolates had an MIC of 1 mg ⁄L, c. 1700
isolates had an MIC of 2 mg ⁄L, and none had an
MIC of 4 mg ⁄L. This may indicate a bias in the
reporting for this database.
In a clinical setting, the most important infor-
mation revealed by a phenotypic susceptibility
test is the MIC for a microorganism, which is the
result of the presence or absence of resistance
mechanisms or intrinsic resistance, and deter-
mines whether an E. coli infection can be treated
with a gentamicin dose within a therapeutic index
[1,15]. Further investigations are therefore
required to determine whether E. coli isolates
carrying gentamicin resistance determinants
could have MICs of 4 mg ⁄L, and whether these
isolates have clinical importance. If so, it should
be determined whether an overlap in MICs
between resistant and susceptible isolates occurs,
and whether it is possible to distinguish between
two such populations in the clinic.
In conclusion, the findings of this study show
that the gentamicin MIC for E. coli isolates is
related to the specific GENR genetic background
in each strain (either aac(3)-II, aac(3)-IV or ant(2¢¢)-I).
The results support the MIC breakpoint sugges-
ted by EUCAST for gentamicin of >4 mg ⁄L, and
not the recommended CLSI breakpoint of
‡16 mg ⁄L.
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Table 1. Disk-diffusion zone diameter results obtained for
six Escherichia coli isolates with gentamicin MICs of 8 mg ⁄L
Strain ID Origin
Gentamicin
resistance
gene
SRGA zone
diameter
(mm)
CLSI zone
diameter
(mm)
73 13 664 Veterinary aac(3)-IV 17 (R) 11 (R)
73 14 803 Veterinary aac(3)-IV 20 (I) 13 (I)
75 10 588 Veterinary aac(3)-IV 20 (I) 13 (I)
BRCG 2 07.03 Wastewater aac(3)-IV 17 (R) 11 (R)
HHCG 2 03.03 Wastewater aac(3)-IV 18 (I) 12 (R)
HHCG 3 08.03 Wastewater ant(2¢¢)-I 19 (I) 11 (R)
SRGA, Swedish Reference Group on Antibiotics; R, resistant; I, intermediate.
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